SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis - PubMed (original) (raw)
Meta-Analysis
. 2019 Nov;7(11):845-854.
doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5.
Tamara Young 1, Hiddo J L Heerspink 2, Bruce Neal 3, Vlado Perkovic 1, Laurent Billot 1, Kenneth W Mahaffey 4, David M Charytan 5, David C Wheeler 6, Clare Arnott 7, Severine Bompoint 1, Adeera Levin 8, Meg J Jardine 9
Affiliations
- PMID: 31495651
- DOI: 10.1016/S2213-8587(19)30256-6
Meta-Analysis
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendon L Neuen et al. Lancet Diabetes Endocrinol. 2019 Nov.
Erratum in
- Correction to Lancet Diabetes Endocrinol 2019; 7: 845-54.
[No authors listed] [No authors listed] Lancet Diabetes Endocrinol. 2019 Dec;7(12):e23. doi: 10.1016/S2213-8587(19)30354-7. Epub 2019 Oct 25. Lancet Diabetes Endocrinol. 2019. PMID: 31669167 No abstract available.
Abstract
Background: The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney failure, particularly the need for dialysis or transplantation or death due to kidney disease, is uncertain. Additionally, previous studies have been underpowered to robustly assess heterogeneity of effects on kidney outcomes by different levels of estimated glomerular filtration rate (eGFR) and albuminuria. We aimed to do a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors on major kidney outcomes in patients with type 2 diabetes and to determine the consistency of effect size across trials and different levels of eGFR and albuminuria.
Methods: We did a systematic review and meta-analysis of randomised, controlled, cardiovascular or kidney outcome trials of SGLT2 inhibitors that reported effects on major kidney outcomes in people with type 2 diabetes. We searched MEDLINE and Embase from database inception to June 14, 2019, to identify eligible trials. The primary outcome was a composite of dialysis, transplantation, or death due to kidney disease. We used random-effects models to obtain summary relative risks (RRs) with 95% CIs and random-effects meta-regression to explore effect modification by subgroups of baseline eGFR, albuminuria, and use of renin-angiotensin system (RAS) blockade. This review is registered with PROSPERO (CRD42019131774).
Findings: From 2085 records identified, four studies met our inclusion criteria, assessing three SGLT2 inhibitors: empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS Program and CREDENCE), and dapagliflozin (DECLARE-TIMI 58). From a total of 38 723 participants, 252 required dialysis or transplantation or died of kidney disease, 335 developed end-stage kidney disease, and 943 had acute kidney injury. SGLT2 inhibitors substantially reduced the risk of dialysis, transplantation, or death due to kidney disease (RR 0·67, 95% CI 0·52-0·86, p=0·0019), an effect consistent across studies (I2=0%, pheterogeneity=0·53). SGLT2 inhibitors also reduced end-stage kidney disease (0·65, 0·53-0·81, p<0·0001), and acute kidney injury (0·75, 0·66-0·85, p<0·0001), with consistent benefits across studies. Although we identified some evidence that the proportional effect of SGLT2 inhibitors might attenuate with declining kidney function (ptrend=0·073), there was clear, separate evidence of benefit for all eGFR subgroups, including for participants with a baseline eGFR 30-45 mL/min per 1·73 m2 (RR 0·70, 95% CI 0·54-0·91, p=0·0080). Renoprotection was also consistent across studies irrespective of baseline albuminuria (ptrend=0·66) and use of RAS blockade (pheterogeneity=0·31).
Interpretation: SGLT2 inhibitors reduced the risk of dialysis, transplantation, or death due to kidney disease in individuals with type 2 diabetes and provided protection against acute kidney injury. These data provide substantive evidence supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes.
Funding: None.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
- Diabetic kidney disease 2.0: the treatment paradigm shifts.
Gilbert RE. Gilbert RE. Lancet Diabetes Endocrinol. 2019 Nov;7(11):820-821. doi: 10.1016/S2213-8587(19)30253-0. Epub 2019 Sep 5. Lancet Diabetes Endocrinol. 2019. PMID: 31495650 No abstract available. - In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes.
Ai Ng SY, Zhu D, Herrington WG. Ai Ng SY, et al. Ann Intern Med. 2020 Feb 18;172(4):JC18. doi: 10.7326/ACPJ202002180-018. Ann Intern Med. 2020. PMID: 32066151 No abstract available.
Similar articles
- Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY, Tecson KM, Lee AY, Lerma EV, Rangaswami J, Lepor NE, Cobble ME, McCullough PA. Kluger AY, et al. Cardiovasc Diabetol. 2019 Aug 5;18(1):99. doi: 10.1186/s12933-019-0903-4. Cardiovasc Diabetol. 2019. PMID: 31382965 Free PMC article. Review. - Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Nuffield Department of Population Health Renal Studies Group, et al. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article. - Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Bae JH, et al. Sci Rep. 2019 Sep 10;9(1):13009. doi: 10.1038/s41598-019-49525-y. Sci Rep. 2019. PMID: 31506585 Free PMC article. - The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
Wang C, Zhou Y, Kong Z, Wang X, Lv W, Geng Z, Wang Y. Wang C, et al. Diabetes Obes Metab. 2019 Apr;21(4):1018-1026. doi: 10.1111/dom.13620. Epub 2019 Jan 16. Diabetes Obes Metab. 2019. PMID: 30565382
Cited by
- Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors.
Choi T, Xie Y, Al-Aly Z. Choi T, et al. Commun Med (Lond). 2024 Sep 11;4(1):179. doi: 10.1038/s43856-024-00599-4. Commun Med (Lond). 2024. PMID: 39261630 Free PMC article. - Imeglimin for Type 2 Diabetes Mellitus: Its Efficacy and Insight Into the Potential Benefit for Renal and Liver Function.
Uto A, Ishinoda Y, Asaga T, Tanahashi Y, Kobayashi A, Meshino H, Okazaki M, Tomita K, Kasuga A, Oshima N. Uto A, et al. Cureus. 2024 Aug 6;16(8):e66322. doi: 10.7759/cureus.66322. eCollection 2024 Aug. Cureus. 2024. PMID: 39238763 Free PMC article. - Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.
Kanimozhi M, Bisht M, Morang S, Thapliyal S, Bassan MS, Handu S. Kanimozhi M, et al. Sultan Qaboos Univ Med J. 2024 Aug;24(3):317-326. doi: 10.18295/squmj.12.2023.093. Epub 2024 Aug 29. Sultan Qaboos Univ Med J. 2024. PMID: 39234312 Free PMC article. Review. - New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.
El Khayari A, Hakam SM, Malka G, Rochette L, El Fatimy R. El Khayari A, et al. Genes Dis. 2023 Nov 23;11(6):101174. doi: 10.1016/j.gendis.2023.101174. eCollection 2024 Nov. Genes Dis. 2023. PMID: 39224109 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous